News
-
-
PRESS RELEASE
PharmaSGP with significant increase in revenues and EBITDA in 2024
PharmaSGP Holding SE achieved significant revenue and EBITDA growth in 2024. Revenues increased by 17.5% to €118.8 million, with adjusted EBITDA reaching €37.2 million. Management foresees further growth in 2025 amidst global uncertainty -
-
-
-
-
-
-
-